glutathione in ovarian cancer a double-edged sword

glutathione in ovarian cancer a double-edged sword Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between cells Frontiers | The strategic breakdown:

Name: glutathione in ovarian cancer a double-edged sword Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between cells Frontiers | The strategic breakdown:
Brand: iglepidom.org
SKU: 21217808045
Price: 28.38 USD
Availability: InStock
Rating: 4.8226 (9 reviews)

Frontiers The strategic breakdown: CHAC enzymes as regulators of glutathione homeostasis and disease implications glutathione in ovarian cancer a double edged sword Peroxidases: An Emerging and Promising Therapeutic Target for Pancreatic Treatment Oxidative cell death in cancer: Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance ScienceDirect Cysteine metabolic circuitries: druggable targets in cancer British Journal of Cancer

SKU: 21217808045 · From iglepidom.org

4.8

USD28.38 USD53.38

Pay in 4 interest-free payments of $7.09 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

The no observed adverse effect level (NOAEL) was determined to be 540 mg/kg, equivalent to 24 times the human clinical dose (448 mg/person/28 days), supporting the safety margin of rotigotine behenate loaded in PLGA microspheres and its potential for advancement into phase I clinical trials for PD 137